Oxymatrine therapy for chronic hepatitis B: A randomized double-blind and placebo-controlled multi-center trial

Table 1 Negative conversion rates of serum HBsAg and comparison among capsule oxymatrine group, injection oxymatrine group and placebo group

Index	Group	Positive number	Number of negative conversion	Negative conversionrate (%)	Comparison among 3 groups
					χ²	P value
HBsAg	Capsule	101	2	1.98
	Injection	30	1	3.33		0.269
	Placebo	67	0	0.00
HBV DNA	Capsule	101	39	38.61
	Injection	30	13	43.33	22.716	0.001
	Placebo	67	5	7.46
HBeAg	Capsule	94	30	31.91
	Injection	28	11	39.29	17.042	0.001
	Placebo	62	4	6.45

The comparison of negative conversion rates of serum HBsAg, HBV DNA and HBeAg was performed with χ² test, statistic was χ².

Table 2 Normalization rate of serum ALT and comparison among capsule oxymatrine group, injection oxymatrine group and placebo group

Group	Number of ALT abnormality before treatment	Number of ALT normalization after treatment	Normalizationrate (%)	Comparison among 3 groups
				χ²	P value
Capsule	102	78	76.47
Injection	30	25	83.33	28.352	0.001
Placebo	65	26	40.00

The comparison of ALT normalization rate was performed with χ² test, statistic was χ².

Table 3 Comparison of therapeutic effect among 3 groups with chronic hepatitis B

Group	Complete response	Partial response	Non-response	Comparison among 3 groups
				χ²	P value
Capusle (n = 102)	25 (24.51%)	59 (57.84%)	18 (17.65%)
Injection (n = 30)	10 (33.33%)	15 (50.00%)	5 (16.67%)	35.957	0.0001
Placebo (n = 67)	2 (2.99%)	28 (41.79%)	37 (55.22%)

The comparison of therapeutic effect among 3 groups was performed with K-W test, statistic was χ².